Attorney's Docket No. 2000DE133



□ Duplicate **PATENT** 

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**Box Patent Application** Commissioner for Patents Washington, D.C. 20231

## **NEW UTILITY PATENT APPLICATION TRANSMITTAL**

Sir:

Transmitted for filing on October 24, 2001 is the patent application of

Inventors: Martin U. SCHMIDT

**Peter KEMPTER** Carsten PLUEG **Roland BORN** 

MIXED CRYSTALS OF BENZIMIDAZOLONEDIOXAZINE For:

**COMPOUNDS** 

1. This new application is for a(n)

Original (non-provisional)

Divisional

Continuation

Continuation-in-Part

2. Papers enclosed that are required for filing date under 37 CFR 1.53(b) (Regular)

Pages of Specification and Claims (18 in number)

Page of Abstract

sheet of drawing

3. Additional papers enclosed:

**Preliminary Amendment** 

Information Disclosure Statement


Form PTO-1449

References Cited

4. Declaration or Oath:

**Enclosed - EXECUTED BY INVENTORS** 

 $\bar{X}$ Not Enclosed





Country	Application No.	Filed
Federal Republic of Germany	100 52 858.9	October 24, 2000

### 7. Fee calculation

CLAIMS AS FILED							
Basic Filing Fee					\$ 740.00		
Number Filed		NumberExtra		Rate			
Total Claims:	18	Minus 20	= 0	X \$ 18.00	- 0 -		
Independent Claims:	1	Minus 3	= 0	X \$ 84.00	- 0 -		
Multiple Dependent Claims (if any) +\$280.00				- 0 -			
TOTAL FEE DUE					\$740.00		

- ☐ Amendment canceling extra claims is enclosed.
- ☐ Amendment deleting multiple-dependencies is enclosed.
- ☐ Fee for extra claims is not being paid at this time.

## Filing Fee Calculation

\$740.00

- 8. Fee Payment Being Made at this Time
  - □ Not enclosed -- No filing fee is to be paid at this time.
  - x Enclosed

x Basic Filing Fee

\$740.00

Assignment Recordation Fee

0.00

## **Total Fees Enclosed**

<u>\$740.00</u>

- 9. Method of Payment
  - <u>x</u> The total filing fee calculated above is authorized to be charged to Deposit Account No. 03-2060 for which purpose a <u>duplicate</u> copy of this cover sheet is attached.

# 10. Authorization to charge additional fees/instructions as to overpayment

The Commissioner is also authorized to credit any overpayments or charge any additional fees required under 37 CFR 1.16 (application filing fees) or 37 CFR 1.17 (application processing fees) during the prosecution of this application, including any related application claiming benefit hereof pursuant to 35 USC §120 (e.g., continuations, divisionals and/or CIPs under 37 CFR §1.53(b) and/or continuations, divisionals and/or CIPs under 37 CFR §1.53(b)) to maintain pendency hereof of any such related application.

Respectfully submitted,

Anthony A. Bisulca

Registration No. 40,913

# (CUSTOMER NUMBER 25,255)

Clariant Corporation Industrial Property Department 4331 Chesapeake Drive Charlotte, North Carolina 28216 Telephone: 704/395-6701

Facsimile:

704/395-6727

#### **CERTIFICATION UNDER 37 CFR 1.10**

Express Mail Mailing Label Number: ET404016687US

aris

Date of Mailing: October 24, 2001

I hereby certify that on the date indicated above, this new U.S. patent application and the papers indicated as enclosed therein, is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" addressed to: Commissioner for Patents, Box Patent/Application, Washington, D.C. 20231, in accordance with 37 CFR 1.10.

Signature of Person Mailing the Application

Vicki L. Sgro

Typed Name of Person Mailing the Application

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Express Mail Mailing Label Number: **ET404016687US** 

Date of Mailing: October 24, 2001

ET 404016687 US

## **CERTIFICATION UNDER 37 CFR 1.10**

I hereby certify that on the date indicated above, this NEW UTILITY PATENT APPLICATION TRANSMITTAL and the papers indicated as enclosed therein, of:

Inventors:

Martin U. SCHMIDT

Peter KEMPTER Carsten PLUEG Roland BORN

For:

MIXED CRYSTALS OF BENZIMIDAZOLONEDIOXAZINE

COMPOUNDS

is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" addressed to the: Commissioner for Patents, Box Patent Application, Washington, D.C. 20231, in accordance with 37 CFR 1.10.

Vicki L. Sgro